GILD
$144.63-0.08%
as of close, Oct 5, 2026
☾ AH $144.63 -0.08%
GILD — Gilead Sciences Inc. price, chart and key statistics
Technical analysis2
Overlay lines0
Addendum charts0
VolumeDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDDEDEDEDED
60.070.080.090.0100.0110.0120.0130.0140.0150.00100.0M$144.63—20162019202120242026
2026-10-05
Price$144.63
MA20$136.21
MA50$130.76
Vol20.5M
Key stats#
Price data
- Price
- $144.63
- YTD price return
- +17.83%
- YTD total return
- +19.95%
- Next earnings
- Oct 29, 2026
- Market cap
- 179.3B
- Enterprise value
- 202.9B
- Shares outstanding
- 1.2B
- 52W low
- $109.66
- 52W high
- $157.29
- From 52W high
- -8.05%
- From 52W low
- +31.89%
- 52W range
- 73%
- Beta
- 0.32
Volume
- Rel volume
- 1.00×
- 30D volume
- 5.7M
- 30D $ vol
- 842.1M
Insider trading
- Insider net 1W
- −$2.2M
- Insider net 1M
- −$3.1M
- Insider net 3M
- −$15.7M
- Insider net 1Y
- −$70.7M
Form 4 transactions by trade date, as filed; latest on file 2026-10-01.
Fundamentals
- Sales (ttm)
- 30.5B
- Sales/share
- $24.56
- EPS (ttm)
- -$2.59
- FCF (ttm)
- 12.9B
- FCF/share
- $10.44
- Book value/share
- $9.54
- Net margin
- -10.64%
- ROE
- -27.39%
- ROA
- -6.56%
- Debt / equity
- 2.01×
- Current ratio
- 1.27
Growth (CAGR, ttm) · 10Y
- Sales
- +5.53%+3.61%+2.72%-0.61%
- FCF
- +38.18%+13.18%+8.85%-3.34%
- Shares
- -0.07%-0.16%-0.22%-0.62%
Per-share growth (CAGR, ttm) · 10Y
- Sales/share
- +5.60%+3.78%+2.94%+0.01%
- FCF/share
- +38.27%+13.37%+9.09%-2.73%
- Book value/share
- -39.85%-17.48%-9.50%-2.08%
- Dividend/share
- +3.21%+2.85%+2.98%+6.23%
- Price
- +27.44%+24.63%+16.50%+6.47%
- Total return
- +30.60%+28.62%+20.73%+10.31%
Fundamentals end at the last reported quarter; price and total return end at the latest close.
Valuation
- P/E (ttm)
- -55.8×
- P/OI (ttm)
- 15.1×
- Fwd P/E
- 14.6×
- P/S (ttm)
- 5.9×
- P/B (mrq)
- 15.2×
- P/FCF (ttm)
- 13.9×
- EV/EBITDA (fy)
- 740.6×
- EV/Sales (ttm)
- 6.7×
- FCF yield (ttm)
- 7.22%
- Dividend yield (fwd)
- 2.27%
- Dividend yield (ttm)
- 2.25%
- Dividend/share (fwd)
- $3.28
- Buyback yield (realized, 1y)
- 0.07%
- Shareholder yield (realized, 1y)
- 3.03%
- Buyback yield (cash, ttm)
- 0.63%
- Shareholder yield (cash, ttm)
- 2.90%
Vs own 10Y history
- P/E
- 35th
- P/OI
- 62nd
- P/S
- 97th
- P/B
- 99th
- P/FCF
- 86th
Bar = where today’s multiple sits in GILD’s own 10-year range:near a decade-low (cheap)→near a decade-high (rich).
Performance · price return · as of 2026-10-05#
1D
-0.08%
5D
-4.98%
1M
-4.22%
3M
+10.18%
YTD
+17.83%
1Y
+28.34%
5Y
+114.58%
Recent filings#
- Oct 1Insider sale · O'Day Daniel Patrick (Chairman & CEO · Director) sold 15,000 shares for $2.2M at $147.72–$148.63 under a 10b5-1 plan
- Sep 15Insider sale · Dickinson Andrew D (Chief Financial Officer) sold 3,000 shares for $436K at $145.29 under a 10b5-1 plan
- Sep 15Insider sale · Mercier Johanna (Chief Comm & Corp Aff Officer) sold 3,000 shares for $433K at $143.69–$145.29 under a 10b5-1 plan
- Sep 1Insider sale · O'Day Daniel Patrick (Chairman & CEO · Director) sold 15,000 shares for $2.2M at $147.51–$149.38 under a 10b5-1 plan
- Aug 26Insider sale · WELTERS ANTHONY (Director) sold 18,000 shares for $2.7M at $148.24–$148.82 under a 10b5-1 plan
Financial statements
Open full GILD financials →Loading financial statements…
Related Healthcare#
| Ticker | Name | 1M | 1D |
|---|---|---|---|
| LLY | Eli Lilly and Company | -0.54% | +0.02% |
| JNJ | Johnson & Johnson | -8.10% | -1.21% |
| ABBV | AbbVie Inc. | +3.63% | +1.12% |
| MRK | Merck & Co. Inc. | -7.18% | -3.30% |
| UNH | UnitedHealth Group Incorporated Common Stock (DE) | -4.67% | +1.80% |
| TMO | Thermo Fisher Scientific Inc. | +10.26% | +3.35% |
| AMGN | Amgen Inc. | -7.83% | -0.01% |
| ABT | Abbott Laboratories | -7.60% | +2.67% |
